- Home
- CSTL vs PFLT Comparison
CSTL vs PFLT Comparison
Compare CSTL & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- PFLT
- Stock Information
- Founded
- CSTL 2007
- PFLT 2010
- Country
- CSTL United States
- PFLT United States
- Employees
- CSTL N/A
- PFLT N/A
- Industry
- CSTL Medical Specialities
- PFLT Finance: Consumer Services
- Sector
- CSTL Health Care
- PFLT Finance
- Exchange
- CSTL Nasdaq
- PFLT Nasdaq
- Market Cap
- CSTL 697.9M
- PFLT 1.0B
- IPO Year
- CSTL 2019
- PFLT N/A
- Fundamental
- Price
- CSTL $21.82
- PFLT $9.78
- Analyst Decision
- CSTL Strong Buy
- PFLT Buy
- Analyst Count
- CSTL 6
- PFLT 6
- Target Price
- CSTL $37.67
- PFLT $10.96
- AVG Volume (30 Days)
- CSTL 449.5K
- PFLT 887.3K
- Earning Date
- CSTL 11-03-2025
- PFLT 08-11-2025
- Dividend Yield
- CSTL N/A
- PFLT 12.58%
- EPS Growth
- CSTL N/A
- PFLT N/A
- EPS
- CSTL N/A
- PFLT 0.81
- Revenue
- CSTL $346,269,000.00
- PFLT $247,973,000.00
- Revenue This Year
- CSTL N/A
- PFLT $43.86
- Revenue Next Year
- CSTL N/A
- PFLT $11.49
- P/E Ratio
- CSTL N/A
- PFLT $12.03
- Revenue Growth
- CSTL 20.40
- PFLT 48.88
- 52 Week Low
- CSTL $14.59
- PFLT $8.82
- 52 Week High
- CSTL $35.84
- PFLT $11.90
- Technical
- Relative Strength Index (RSI)
- CSTL 51.42
- PFLT 31.44
- Support Level
- CSTL $21.28
- PFLT $9.61
- Resistance Level
- CSTL $24.74
- PFLT $10.23
- Average True Range (ATR)
- CSTL 1.09
- PFLT 0.14
- MACD
- CSTL -0.34
- PFLT -0.04
- Stochastic Oscillator
- CSTL 15.61
- PFLT 24.64
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.